|
July 24, 2006
FOR IMMEDIATE RELEASE
Salex Pharmaceuticals and Colon Cancer Alliance Team Up to Fight Colorectal Cancer
(New York) - (July 24, 2006) - The Colon Cancer Alliance (CCA) and Salix Pharmaceuticals are proud to announce the teaming of the two organizations in the mission to end the suffering caused by colorectal cancer. Through this partnership, Salix will help to support the CCA's awareness efforts, research and patient-focused initiatives, aiming to highlight this important issue until there is no longer a need.
The first of many programs launched at the annual Digestive Disease Week (DDW) 2006 meeting in May. Salix Pharmaceuticals contributed $20 for every attendee who stopped by their booth during the conference. Visitors to the Salix booth also received information about the Colon Cancer Alliance and its programs.
Digestive Disease Week is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Over 16,000 attendees were on hand.
"We are encouraged by the success of our first program and look forward to developing many others together," stated Carolyn Logan, President & CEO, Salix Pharmaceuticals Inc. "Awareness and education on the importance of screening are key in the fight against colon cancer."
Colon cancer is the second leading cause of cancer death in the United States and will lead to more than 56,000 deaths in 2006. Every four minutes, someone is diagnosed with the disease and every nine minutes, someone dies. Yet, colorectal cancer is highly preventable and treatable. Regular screening, combined with a healthy lifestyle, can prevent more than half of colon cancer deaths. That means as many as 30,000 lives could be saved each year if more people received regular screenings.
"Colorectal cancer is a preventable disease yet thousands across the country are missing life-saving opportunities because they aren't getting screened. The Colon Cancer Alliance, with help of partners like Salix, is working to change this," said Amy Kelly, Co-Founder and Executive Director of the Colon Cancer Alliance.
About Salix Pharmaceuticals, Inc.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's 100-member gastroenterology specialty sales and marketing team.
About the Colon Cancer Alliance
The Colon Cancer Alliance (CCA) is a national patient advocacy organization, with chapters located across the country, and the official patient support partner of Katie Couric's National Colorectal Cancer Research Alliance (NCCRA). CCA is dedicated to ending the suffering caused by colorectal cancer. The Colon Cancer Alliance brings the voice of survivors to battle colon cancer through patient support, education, research and advocacy. To find out more, call the Colon Cancer Alliance's toll-free helpline at 1-877-422-2030 or visit the Web site at www.ccalliance.org.
###
Contact:
Amy E. Kelly
Co-Founder and Vice President
Colon Cancer Alliance
954-341-0212
akelly@ccalliance.org
Alissa Maupin
Salix
919-923-6785
amaupin@medthink.com
 Return to Press Releases
©2008 Colon Cancer Alliance
Patients | Friends and Family | You Are Not Alone | About CCA | What is Colorectal Cancer? | How Can I Help? | News and Events | Contact Us | Home
|
